Windjammer Capital has announced it has acquired Bio X Cell (BXC).
BXC, founded in 1997 and based in Lebanon, N.H., is a producer of monoclonal antibodies for use in both in vivo and in vitro pre-clinical research applications.
Windjammer, based in Newport Beach, Calif., and Waltham, Mass., is a private equity firm focused on the middle market. Founded in 1990, the firm prefers to make control equity investments of $50 million to $200 million in niche manufacturing, business services and value-added distribution.
Terms of the acquisition were not disclosed.